VPS34 Inhibitors Blocking Double-Membrane Vesicle Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for therapeutic agents that can inhibit the replication and transmission of SARS CoV-2 and related coronaviruses by targeting the formation of double membrane vesicles essential for viral replication and entry into host cells.
Innovation Solution
The use of VPS34 inhibitors, represented by specific compounds of Formula I, to block the formation of double membrane vesicles required for viral replication and entry, thereby inhibiting viral replication, transmission, and protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VPS34 inhibitors are used to block double membrane vesicle formation, then viral replication and transmission are inhibited, but potential off-target effects on endosomal pathway may occur
Solution Approach 1:
The patent modifies the chemical structure of VPS34 inhibitors by changing parameters such as the aromatic ring substitution patterns (positions 2,4,6 vs 3,5), alkyl chain lengths (C1-C6), and functional group configurations. These parameter changes create a series of compounds with varying affinities and selectivities, allowing optimization to reduce off-target effects while maintaining viral replication inhibition.
Solution Approach 2:
The patent introduces local modifications at specific positions of the VPS34 inhibitor molecule (e.g., substituting aromatic rings at different positions, adding specific functional groups at defined locations). These local quality changes allow selective interaction with VPS34 while minimizing interference with the endosomal pathway, achieving specificity in the therapeutic effect.
2Reliability
If VPS34 inhibitors are administered to treat coronavirus infections, then viral replication is blocked, but potential toxicity and side effects may arise
Solution Approach 1:
The patent develops a series of VPS34 inhibitor compounds that can be rapidly synthesized and administered. The compounds are designed with appropriate pharmacokinetic properties for short-term therapeutic use, minimizing accumulation and chronic toxicity while maintaining effective viral replication block during the infection period.
Solution Approach 2:
The patent systematically varies chemical parameters including molecular weight, lipophilicity, and functional group composition across the VPS34 inhibitor series. These parameter changes optimize the balance between therapeutic efficacy (viral replication block) and safety profile (toxicity and side effects), allowing selection of compounds with favorable risk-benefit ratios.
3Reliability
If double membrane vesicles are formed for viral replication, then viral RNA is protected from degradation, but viral spread and transmission are enabled
Solution Approach 1:
The patent employs VPS34 inhibitors that prevent the formation of double membrane vesicles before the viral replication cycle can proceed. By blocking VPS34 kinase activity at the initiation stage, the inhibitors prevent both the protective function (RNA degradation protection) and the harmful function (viral spread through vesicle-mediated transmission), achieving prevention rather than treatment of existing viral structures.
Data Source
AI summary
Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.